Morningstar1mon
TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases
a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, today announced the closing of its $31 million (£25 million) seed funding round.
BBC1y
Electrical sources and internal resistanceElectrical sources and internal resistance
The voltage across the ends of the cell is called the terminal potential difference, \(V_{tpd}\). \(V_{tpd}\) can also be calculated as \(I R\) where \(R\) is the load resistance. Voltage is a ...
BPGbio, Inc.: BPGbio to Present Novel E2-based Targeted Protein Degradation Program at 5th Annual TPD and Induced Proximity Summit in Europe
E2-based therapeutics show early promise in addressing neurological disorders and oncology applications. BPGbio's protein homeostasis program includes 1,000+ proprietary Ro3 fragments, which ...
News Medical29d
TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases
TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of ... and Will McEwan (UK Dementia Research Institute at the University of Cambridge).